

LETTER TO THE EDITOR

Open Access



Pathogenic somatic alterations of DDR genes in lung cancer are significantly different from germline mutations and are associated with more unstable genomes

Huaqing Wang¹, Yue Zhao², Fei Wang³, Xiaofeng Zhu³, Ningning Luo³, Tingting Sun³, Chuang Qi³ and Xin Li^{4*}

To the Editor

The defects DNA-damage repair (DDR) genes would drive tumor formation and are associated with increased genomic instability and tumor mutational burden (TMB) in cancer [1]. Although, alterations of DDR genes are common in NSCLC, the differences between the germline and somatic alterations are poorly characterized.

The DNA sequencing data of 540 genes from 5235 lung cancer patients were retrospectively collected and 276 DDR genes were analyzed [2]. The variations were annotated as pathogenic (P), likely pathogenic (LP), and non-pathogenic (NP) according to ACMG (American College of Medical Genetics) guideline. The patients were divided into 3 groups (Table 1): DDR-germline (P&LP germline variants, N=650), DDR-somatic group (only P&LP somatic variants, N=1489) and the non-DDR group (NP variants, N=3096). The DDR-somatic group had a higher median age and the highest proportion of males, stage IV and LUSC patients.

The most commonly germline alterations were found in BRCA2 (8.46%), ERCC2 (8.15%) and IDH1 (8%), while in the somatic mutations, TP53 (89.05%) showed the highest frequency (Fig. 1A, B). Among the ten functional categories of DDR genes, the mutations of Fanconi anemia (FA) (234, 36.00%) and homology-dependent recombination

(HR) (249, 38.31%) signaling were enriched in germline, while other categories (1417, 95.10%) were more common in somatic alterations.

In pairwise comparisons of the three groups, 28 actionable mutations were assessed based on OncoKB [3]. DDR-somatic group was more likely to have alterations in *PTEN* (OR=0.46), *FGFR1* (OR=0.48), *NTRK1* (OR=0.46) compared with DDR-germline group. Taken non-DDR group as reference, mutations in *ALK* (OR=1.94), *CDK12* (OR=2.62), *STK11* (OR=1.58) were more common in DDR-germline group, but *CDKN2A* (OR=2.13), *NF1* (OR=2), *NTRK3* (OR=2.06) in DDR-somatic group (Fig. 1C).

The tumor mutational burden (TMB) was statistically different among the three groups ($P < 2.22 \times 10^{-16}$). The DDR-somatic group exhibits the highest median TMB (12.39) compared with 7.44 in DDR-germline and 5.24 in non-DDR group. In addition, the proportion of MSI-H patients in DDR-somatic group is the highest (0.94%) compared with 0.62% in DDR-germline group and 0.23% in non-DDR group ($P = 0.0040$) (Fig. 2A).

The genetic data of 1053 lung cancer patients were downloaded from TCGA. The TCGA cohort was stratified into DDR-somatic and non-DDR groups according to the pathogenic annotation by Clinvar. Ten types of immune cells were found significantly associated with DDR status (Fig. 2B), Macrophages M0 ($P = 0.0126$), Macrophages M1 ($P = 0.0002$) and CD8 T cells ($P = 0.0087$) showed higher proportions in DDR-somatic group.

*Correspondence: 13920740907@163.com

⁴ Cardiothoracic Surgery Department, Tianjin Medical University General Hospital, Tianjin, China

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.





Fig. 1 DDR gene mutation landscapes of the DDR-germline (A) and DDR-somatic (B) groups and the comparison of the alterations in actionable genes among the three groups (C)

**Table 1** Comparison of clinical data for NSCLC patients in non-DDR, DDR-somatic, and DDR-germline groups

Characteristics	N	Level	non_DDR N (%)	DDR_somatic N (%)	DDR_germline N (%)	P value
Total	5235		3096	1489	650	
Age	5232		62 (16–94)	64 (23–107)	62 (27–92)	1.43E–07
Gender	5235	Female	1590 (51.36%)	554 (37.21%)	293 (45.08%)	1.9443E–18
		Male	1506 (48.64%)	935 (62.79%)	357 (54.92%)	
Stage	2380	I	255 (19.26%)	48 (6.43%)	48 (15.48%)	5.2446E–13
		II	129 (9.74%)	59 (7.91%)	29 (9.35%)	
		III	242 (18.28%)	157 (21.05%)	64 (20.65%)	
		IV	698 (52.72%)	482 (64.61%)	169 (54.52%)	
Diagnosis	3888	NSCLC	2266 (98.65%)	1075 (96.85%)	475 (98.75%)	0.00071134
		SCLC	31 (1.35%)	35 (3.15%)	6 (1.25%)	
Subtype	3544	LUAD	1923 (91.22%)	827 (82.95%)	382 (87.02%)	1.0291E–09
		LUSC	148 (7.02%)	140 (14.04%)	50 (11.39%)	
		Others	37 (1.76%)	30 (3.01%)	7 (1.59%)	

The differences in the mutation profile between the DDR-germline and DDR-somatic groups and the distinct actionable genes may indicate the different target-therapy choices for NSCLC patients. Besides, patients with somatic pathologic mutations exhibit the highest genome instability, including the highest TMB and the most MSI-H, and superior immune microenvironment consist of higher proportions of macrophages and CD8 cells infiltration. According to a previous report, patients with pathologic DDR mutations had higher objective response rate, longer median progression-free survival and overall survival with PD-L1 therapy [1]. This may indicate patients with somatic DDR alterations may better benefit from the immune checkpoint inhibition in NSCLC.

Acknowledgements

We thank Mr. Ran Ding, Mr. Guanghua Lu, and Mr. Wanglong Deng from Simcere Diagnostics for the kindly assistance.

Author contributions

HW: Conceptualization, Writing—Original Draft. YZ: Visualization, Investigation. XZ, NL: Data analysis, Writing—Original Draft. FW, TS: Writing—Original Draft. CQ: Methodology, XL: Conceptualization, Writing- Reviewing and Editing. All author read and approved the final manuscript.

Funding

This work was funded by the National Natural Science Foundation of China (No. 82070206) and Tianjin Key Medical Discipline(Specialty) Construction Project (No.TJYXZDXK-053B).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This study used desensitized patient data for analysis and the ethics approval was waived.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Oncology, Tianjin Union Medical Center of Nankai University, Tianjin, China. ²Department of Oncology, Qinhuangdao Fourth Hospital, Qinhuangdao, China. ³The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China. ⁴Cardiothoracic Surgery Department, Tianjin Medical University General Hospital, Tianjin, China.

Received: 5 August 2022 Accepted: 6 August 2022

Published online: 06 September 2022

References

1. Ricciuti B, Recondo G, Spurr LF, et al. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. *Clin Cancer Res.* 2020;26(15):4135–42. <https://doi.org/10.1158/1078-0432.CCR-19-3529>.
2. Knijnenburg TA, Wang L, Zimmermann MT, et al. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. *Cell Rep.* 2018;23(1):239–254 e236. <https://doi.org/10.1016/j.celrep.2018.03.076>.
3. Chakravarty D, Gao J, Phillips SM, et al. OncoKB: a precision oncology knowledge base. *JCO Precis Oncol.* 2017. <https://doi.org/10.1200/PO.17.00011>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

